Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India

NCT05040126 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

400

Enrollment

OTHER_GOV

Sponsor class

Conditions

Pre-Extensively Drug-Resistant Pulmonary TB
Treatment Intolerant Multidrug-Resistant Pulmonary TB
Non-responsive Multidrug-Resistant Pulmonary TB

Interventions

DRUG: Linezolid
DRUG: Bedaquiline
DRUG: Pretomanid

Sponsor

Tuberculosis Research Centre, India

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]